GRASSILLI EMANUELA

Ruolo:
Docente a contratto
Settore scientifico disciplinare:
Patologia generale (MED/04)
Telefono:
Stanza:
  • U08, Piano: 4, Stanza: 4008

Pubblicazioni

  • Ilari, A., Cogliati, V., Sherif, N., Grassilli, E., Ramazzotti, D., Cordani, N., et al. (2024). Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer. BIOMEDICINES, 12(2) [10.3390/biomedicines12020272]. Dettaglio

  • Grassilli, E., Cerrito, M. (2023). "Ironing out" fasting-induced persister cancer cells to render chemotherapy effective: is this the solution?. EBIOMEDICINE, 90(April 2023) [10.1016/j.ebiom.2023.104542]. Dettaglio

  • Betzler, A., Strobel, H., Abou Kors, T., Ezić, J., Lesakova, K., Pscheid, R., et al. (2023). BTK Isoforms p80 and p65 Are Expressed in Head and Neck Squamous Cell Carcinoma (HNSCC) and Involved in Tumor Progression. CANCERS, 15(1) [10.3390/cancers15010310]. Dettaglio

  • Brunner, C., Betzler, A., Brown, J., Andreotti, A., Grassilli, E. (2022). Editorial: Targeting Bruton Tyrosine Kinase. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 10 [10.3389/fcell.2022.909655]. Dettaglio

  • Scagliotti, A., Capizzi, L., Cazzaniga, M., Ilari, A., De Giorgi, M., Cordani, N., et al. (2022). Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation. FRONTIERS IN ONCOLOGY, 12 [10.3389/fonc.2022.998274]. Dettaglio

Progetti di ricerca

p65BTK as an actionable target in ovarian cancer
Anno: 2017
Bando: 2017-048 - Rivkin Center for Ovarian Cancer - Pilot Study Awards
Enti finanziatori: RIVKIN CENTER FOR OVARIAN CANCER
Targeting p65BTK in Non-Small Cell Lung Cancer
Anno: 2015
Bando: The Lung Cancer Research Foundation
Enti finanziatori: THE LUNG CANCER RESEARCH FOUNDATION